XXXX pipeline the you you, you Good us. and our joining Thank to we’ve quarter should will I be what drug Today, I which Slides of Slides briefly in to summarizing to expecting over development Jim. background months. Thank have are programs plan first XX slides, XX content in presented. for afternoon. the be previously share next the what X accomplished I XX. highlight nine
website stated, our you more. on Jim As slides posted the study if are want to them
or development Let’s X. have improving Processa and/or our patients opportunities includes within drugs of condition. survival life of medical have This Processa independent is need company, treatment to are focused our goal our staff to first either a Slide that of on the different blockbusters. have the medical shots or we on each state option a potential thing who to drug. better unmet five or which Processa who an each a Each investors, five drug five patients unmet for market go option. no drug a means our There’s potential with quality is pipeline a of one addresses need being have slide, billion These treatment giving blockbuster size more. need $X that
simultaneously developing the the questions. process. importantly, XX science to best started develop development a is FDA process are approach provide number that we all when and our ago contracts two worked More answer to This through scientific but we FDA going the way determining all are stages, now answer regulatory various and years of on at five to drugs regulatory we clinical
review expect March to of guidances. I development at the multiple each milestones and I these the briefly of of end to discuss will our to a drug number that from have now led within pipeline. We contracts the year. milestones achieve Our August FDA we as near-term
Next remind describes the the on of would used we pipeline. to I I like slide. slide. have point everyone, out the covered X the To Since five slide, to have our other some item only criteria in drugs already select Slide key one that
of The efficacy similar This evidence second drugs drug for criteria evidence. red five pharmacology. targeted for some a is the population in in with stating efficacy that clinical the box very means each of or there the
Next slide.
Now let’s look pipeline. our of a at summary
in drugs development. four have clinical We
XXXX. are what capecitabine, generation next of we rebranding have We which previously we called
And And have are in drug Three stage. them. XXXXX is of gastroparesis, XXX we unmet the one treatment disease. medical the necrobiosis lipoidica of cancer. treatment adverse a an the for XXX, events fourth of need where the associated rare drugs serious pre-IND of have fifth for the ulcerative have XXXX. the is options We and with treatment for present XXXXX orphan treatment The
Next slide. This we the slide highlights provides achieved quarter what the XXXX. you of of have first with in
have obtaining our with the key to assist in and moved our closer submission. NDA design We data FDA, of us to trials the pivotal our discussions
generation de in and which Phase XXXX novo XB generation we the next amended capecitabine patients next program, protocol. the to began associated amended have with capecitabine, understand better formation protocol as enrolling we of the DPD defined previously For
manner. For in final and patients for timely enrollment XXX, order our analysis to potential interim a complete we’ve expanded our NL more outreach in to ulcerative identify
five For trial versus developing our we XXXX XXXXX, And assays identify that gastroparesis to we’ve enrolled XXXX, to for response if patients potential gemcitabine. we far. for predict biomarkers so determine began could would
of evaluation development the continue our potential which will In addition, we increase will regulatory FDA paths, for approval. and probability
you give next to our first generation like an would I update cancer slide. program. capecitabine Next on
we previously have about billion in the As generation is $X for colorectal market stated, market. capecitabine next cancer
capecitabine with and be potentially less dose capecitabine existing efficacy better next to greater the effects limiting higher than potency. expect We generation given side
non-cancer have Next slide. Xb and increase limiting to-date, killing hours. effects we trial decrease From a XX metabolites have caused side for Phase we an seen dose in the to XX the that our potency seen in
protocol and However, for will days increased The seven one, last next and all chemotherapy, generation for seven the potency dose not chemotherapy PCSXXXX capecitabine. all days for maximum these treatment. of that tolerated did metabolism inhibit two effects regimens amended of determines,
in Next the from generation quarter we’ve next months, next Processa first the over slide. nine accomplished to what XXXX and This slide expect capecitabine. summarize the of what
regimen for trial. identified the next an we next personalized First, chemotherapy. killing the to QX? seven initial potency achieve what the Two, amended we’ve to we be the the expedite inhibit the PCSXXXX in days our do that regimens completed dose next used generation formation we to Xb dose increase limiting during And year? sites PCSXXXX amended for the the end in in defining enrolling our and to have One, be individualized approach of capecitabine in we’ve we the What achieve hope capecitabine. capecitabine of expect the Xb regimen protocol. generation dosage begun mid-XXXX, the of study already will using will the have non-cancer of side should Phase to Phase Well, and add we By preliminarily generation enrollment. Phase dosage patients hope cancer rest the a to of tolerated clinical maximum of three, that of protocol, metabolites identify and the cause or all we year, effects metabolites treatment killing X evaluation
Next slide.
Let of me NL. now review treatment PCSXXX for the ulcerative
natural is one healing a of in first rare the less billion this recall, may X% than two which of NL you probably open ulcers after $X patients. to the in disease years market onset occurs during As ulcerative
same the efficacy dose use limiting limit care, ulcers PTX, of the of FDA of call Next can because as slide. treatments amounts a resulting no better of PTX. no PCSXXX profile. use metabolite the are administered. There closing treatments works pentoxifylline different some The analog PTX. of their limited and PTX safety safety quantitatively given I a side in the PCSXXX patients, it, qualitatively often as but standard off-label has drugs all dose in metabolite include be deuterated the has profile. metabolites effects have is but that or approved of the off-label
XXXX nine first to what what months. slide This the slide. in quarter with PCSXXX and over Next expect next summarizes we’ve accomplished the of
to in identification our now, five enrolled in eight bringing top in Well, we hope requirements evaluating in to Also, have evaluation to are next what such sites. hope one impact again, been expect have we the to patients analysis. that XXXX? trial data expanded enrollment the XXXX. mid-XXXX, has What a the the of we basic used additional the major reading interim of QX, and screening patients plan on pre-screening screening the in in the XX to the identified months we have seven patient do prior require and We trial. have we determine Xb we have had initiate So we end over interim remedial to meet the pre-screening to sites have into year, At meet be COVID X Phase efforts expect of in enrollment a if end more the five to out, XXXX the Although, with they the in of achieve moving analysis patient from on Phase FDA and at have our and depending that for one patient we enrollment, results our achieved meeting procedure. to our completed on the line FDA to QX? the trial with hope do
off-label reviewing of use potent to X-HTX and other This is Quickly PCSXXXXX slide. Next selective and agonist a treatment treat gastroparesis. X-HTX more agonist gastroparesis. the drugs for
preclinical agonist, has X-HTX studies serious the for to black PCSXXXXX requires only gastroparesis and greater and selectivity Because with lower limited potency much dose higher side much, metoclopramide Other dose of slide. drug warnings use. Next and side than other receptor, drugs. has and X-HTX effects box effects limiting the the in and clinical these treat PCSXXXXX a less approved of
slide. Next
and again, to for months? So, what next five out nine this over enrolled achieve trial have total patients far. we the expect XX achieved we what We’ve of plan the so do
the of top the in study with line rate of We the empty expect of complete the October in the timeframe September, a change year. by readout gastric end enrollment
that rate drug will cancers today sales of for IND, various similar XX% treatment we which I with to for billion number slide. have which is a used This the maximum last cancers across But failure as XX% approximately or for. The be gemcitabine, drug Next fourth second cancer PCSXXXX. used a therapy. a is of an the and line drug drug, a is $X of to first reviewing
Next for have pancreatic an slide. treatment of the PCSXXXX clinical IND presently and been cancer has studies completed. preliminary
cancer efficacy has demonstrated Some populations different been of already in pancreatic patients.
evaluating be assays for we slide. we potential as that Next molecules began specific developing QX, biological biomarkers In will PCSXXXX. for
Thus, hypothesis patients that to PCSXXXX gemcitabine. treated The evaluation will for should response molecules select giving preliminary away initial over patient’s is preferentially some to to gemcitabine. PCSXXXX these Our and a mid-XXXX. completed be with to able assay of us be predict be
We we for can of study the PCSXXXX developed of PCSXXXX. roadmaps have at for the that to number populations, the clinical end expect of for such this to FDA year cancers and next the different our meet development a discuss targeted with
that Next slide. and In can have for PCSXXX a with PCSXXXXX moved effect you generation successfully we enrollment forward, serious see having conclusion, even PCSXXX. on next COVID capecitabine,
the the midyear data to that trials. larger efficacy on us by trials expect the will key We and these year have end design of at help three
deck expect profile. ask provide lastly, the with each pipeline you background concludes that the for remarks. FDA We various along slides, the the all in roadmap highest which are they also last operator in with has of some will our more demonstrating probability to slides have targeted now insight interactions a risk for lines the and more are collaboration us we anticipate pull to but Operator, And the populations path open The slides that discuss will into questions? programs This drug have Q&A. paths information. provide development FDA presented for these please the can phone the for with approvable I’ll an potential not form. approval. that my benefit to I been before will
